Configuration Path of High-Quality Development of Pharmaceutical Manufacturing Enterprises from the Perspective of TOE:Based on a Mixed Research Method of fsQCA and NCA
The high-quality development of pharmaceutical manufacturing enterprises is crucial for promoting the"Healthy China"initiative and achieving the goal of becoming a manufacturing powerhouse.Based on the Tech-nology-Organization-Environment(TOE)theoretical framework,this study employs a mixed research method com-bining NCA and fsQCA,analyzing 231 pharmaceutical manufacturing enterprises to examine the configurational effects of six conditions:digital transformation,innovation investment,entrepreneurial spirit,human capital struc-ture,government subsidies,and regional digital infrastructure on high-quality development.The findings reveal that:(1)No single variable is a necessary condition for high-quality development;however,bottleneck analysis indicates that the level of high-quality development is constrained by entrepreneurial spirit,government support,and the level of regional digital infrastructure.(2)Four modes exist for achieving high-quality development:envi-ronment-oriented,organization-environment ambidextrous-driven,technology-environment ambidextrous,and envi-ronment-technology-organization synergy.Among these,the environment-oriented mode can be further divided into three configurations:organization synergy under environmental leadership,technology-driven under environmental leadership,and environment-driven configurations.The main characteristics include:government financial support is a core condition for high-quality development;and there is a degree of substitutability among the variables of dig-italization,human capital structure,and regional digital infrastructure across different contexts.(3)Two configura-tions lead to non-high-quality development,characterized by:a low level of digital transformation is not a necessary condition for high-quality development;and in the absence of external environmental support and internal organiza-tional synergy,innovation investment in pharmaceutical manufacturing enterprises is unlikely to yield practical re-sults.
万方数据
